All In Biotech

Drug Trial Radar · NCT03912233

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Last checked: Nov 19, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

87

Actual

Start

Apr 30, 2019

Primary completion

Dec 10, 2019

Study completion Dec 10, 2019

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Apr 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis (CF).

Conditions

  • Cystic Fibrosis

Interventions

  • VX-121Drug

    Tablets for oral administration.

  • TEZDrug

    TEZ tablet for oral administration.

  • VX-561Drug

    Tablets for oral administration.

  • TEZ/IVADrug

    Fixed-dose combination tablets for oral administration.

  • IVADrug

    Tablets for oral administration.

  • PlaceboDrug

    Placebos matched to VX-121, TEZ, and VX-561 for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 Through Safety Follow-up (up to Day 75 for Part 1 and up to Day 85 for Part 2)
  2. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)Time frame: From Baseline Through Day 29

Locations

26 sites in 5 countries. Site status is shown where the registry gives one.

  • Keck Medical Center of University of Southern California

    Los Angeles, California

  • Kaiser Permanente

    Oakland, California

  • University of Kentucky.

    Lexington, Kentucky

  • Tulane Medical Center

    New Orleans, Louisiana

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Columbia University Medical Center

    New York, New York

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Santiago Reyes, M.D.

    Oklahoma City, Oklahoma

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Charite Paediatric Pulmonology Department

    Berlin, Germany

  • Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen

    Essen, Germany

  • Pneumologisches Studienzentrum Muenchen-West

    München, Germany

  • Academic Medical Center

    Amsterdam, Netherlands

  • University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis

    Heidelberglaan, Netherlands

  • UMC St. Radboud

    Nijmegen, Netherlands

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • HagaZiekenhuis van den Haag

    The Hague, Netherlands

  • Hospital de Santa Maria

    Lisbon, Portugal

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital

    London, United Kingdom

  • Wythenshawe Hospital

    Manchester, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom

  • All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough

    Penarth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.